• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad , Oct. 17

Cadila Healthcare Ltd (Zydus-Cadila) has received approval from the US Food and Drug Administration to market Zonisamide capsules in the American market, a company release said on Tuesday. The company will market the drug in the strengths of 25, 50 and 100 mg. The drug falls in the anti-epileptic segment. The company will market the drug through its US-based subsidiary Zydus Pharmaceuticals (USA) Inc. This marks the 17th ANDA approval for the group since the commencement of filing process in the financial year 2003-04.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
McDowell & Co re-christened United Spirits

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line